A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home AIMD Companies EnteroMedics EnteroMedics Reports Maestro Obesity Study Showing 25% Reduction in Excess Weight
formats

EnteroMedics Reports Maestro Obesity Study Showing 25% Reduction in Excess Weight

EnteroMedics Maestro Obesity IPG David Prutchi PhD

EnteroMedics reported new clinical trial data for its Maestro system, which is designed to treat obesity through vagus nerve stimulation. The company said that its Maestro RC system lost 25% of their excess weight, or 10% of their total body weight, after 18 months. Patients who received a sham implant lost 12% of excess weight, or 4% of their total weight. The company is running a five-year study of the system.  The system is approved in Europe and Australia, but not the U.S.

 

 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on EnteroMedics Reports Maestro Obesity Study Showing 25% Reduction in Excess Weight  comments